We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

78 hedge funds and large institutions have $113M invested in Fennec Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 6

38% more capital invested

Capital invested by funds: $81.6M → $113M (+$31.3M)

15% more funds holding

Funds holding: 68 → 78 (+10)

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

0.74% more ownership

Funds ownership: 48.53% → 49.27% (+0.74%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
78
Holders Change
+10
Holders Change %
+14.71%
% of All Funds
1.03%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
25
Reduced
24
Closed
6
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
+$11K

Top Buyers

Rank Fund Capital Flow
1
RA
Rosalind Advisors
Ontario, Canada
+$1.8M
2
ACM
AIGH Capital Management
Maryland
+$625K
3
EI
EAM Investors
California
+$538K
4
Citadel Advisors
Citadel Advisors
Florida
+$320K
5
Jane Street
Jane Street
New York
+$241K

Top Sellers

Rank Fund Capital Flow
1
HFA
Harbert Fund Advisors
Alabama
-$1.23M
2
DCM
DG Capital Management
New York
-$513K
3
GJL
Gendell Jeffrey L
-$380K
4
Morgan Stanley
Morgan Stanley
New York
-$290K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$263K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
1
Southpoint Capital Advisors
New York
$33.8M – – –
SCM
2
Solas Capital Management
Connecticut
$18.5M -$123K -18,017 -0.8%
RA
3
Rosalind Advisors
Ontario, Canada
$17M +$1.8M +262,800 +15%
BlackRock
4
BlackRock
New York
$10.2M -$163K -23,851 -2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$8.03M +$16.9K +2,472 +0.3%
ACM
6
AIGH Capital Management
Maryland
$3.75M +$625K +91,395 +25%
State Street
7
State Street
Massachusetts
$2.79M -$11.2K -1,639 -0.5%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.53M -$46.1K -6,735 -2%
HFA
9
Harbert Fund Advisors
Alabama
$2.39M -$1.23M -179,255 -38%
Morgan Stanley
10
Morgan Stanley
New York
$2.11M -$290K -42,395 -14%
LPC
11
Lion Point Capital
New York
$1.62M – – –
GJL
12
Gendell Jeffrey L
$1.16M -$380K -55,515 -28%
Northern Trust
13
Northern Trust
Illinois
$1.09M -$47.2K -6,903 -5%
EI
14
EAM Investors
California
$653K +$538K +78,661 New
Charles Schwab
15
Charles Schwab
California
$509K +$965 +141 +0.2%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$430K -$11.6K -1,694 -3%
HFM
17
Hartford Financial Management
Connecticut
$420K +$5.46K +798 +2%
Jane Street
18
Jane Street
New York
$415K +$241K +35,271 +240%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$389K +$114K +16,593 +55%
Citadel Advisors
20
Citadel Advisors
Florida
$388K +$320K +46,783 New
Barclays
21
Barclays
United Kingdom
$332K +$107K +15,704 +65%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$281K +$3.65K +533 +2%
MHP
23
Manatuck Hill Partners
Connecticut
$251K +$207K +30,200 New
Arrowstreet Capital
24
Arrowstreet Capital
Massachusetts
$225K +$185K +27,055 New
N
25
Nuveen
North Carolina
$216K – – –
1
2 3 4

FENC Hedge Fund Activity: Q2 2025 in Review

78 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2025, worth a combined $113M — up 38% from $81.6M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new FENC positions and 6 closed out — a net gain of 10 holders — while 25 added to existing stakes and 24 trimmed.

The largest buyer was Rosalind Advisors, adding an estimated $1.8M. The largest seller was Harbert Fund Advisors, cutting an estimated $1.23M.

  • 78 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2025, up from 68 in Q1 2025.
  • Funds reported $113M of Fennec Pharmaceuticals stock for Q2 2025, up 38% quarter-over-quarter.
  • 16 funds opened new Fennec Pharmaceuticals positions in Q2 2025 and 6 closed out, a net change of +10 holders.
  • The largest Fennec Pharmaceuticals buyer in Q2 2025 was Rosalind Advisors, an estimated $1.8M added.
  • The largest Fennec Pharmaceuticals seller in Q2 2025 was Harbert Fund Advisors, an estimated $1.23M sold.

Based on aggregated 13F filings for Q2 2025.